Most readers would already be aware that Royalty Pharma's (NASDAQ:RPRX) stock increased significantly by 6.7% over the...
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposesNEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalt
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposesCOPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreemen